NCT03867201CompletedPhase 3
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients
Source: ClinicalTrials.gov · Last updated 16 Oct 2025
Brief summary (registry, in English)
The purpose of this study was to evaluate the efficacy and safety of erenumab in patients with chronic migraine in Asian population.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 557 (actual)
- First submitted
- 25 Feb 2019
- Start date
- 26 Aug 2019
- Primary completion date
- 11 Aug 2021
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Migraine
- NCT number
- NCT03867201
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 557
- From 26 Aug 2019 to the primary completion date, 11 Aug 2021
- 46 sites in 9 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cluster or hemiplegic headache
- Evidence of seizure or major psychiatric disorder
- Cardiac or active hepatic disease
Age
- Older than 50 years of age at migraine onset
Other
- Pregnant or nursing
Who the study is looking for
- History of at least 5 attacks of migraine
- ≥ 15 headache days of which ≥ 8 headache days meet criteria as migraine days during the baseline period
- \>=80% diary compliance during the baseline period
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (46)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.